LAVA Therapeutics (LVTX) Proxy Filing summary

Executive summary

• Entered into a share purchase agreement with XOMA Royalty Corporation, with XOMA commencing a tender offer to acquire all outstanding shares for $1.16 per share plus up to $0.08 per share and a contingent value right (CVR) per share.

• The transaction is subject to shareholder approval at an extraordinary general meeting (EGM), with a proxy statement to be filed for voting on related proposals.

• Forward-looking statements highlight anticipated benefits, timing, and risks associated with the transaction, including potential disruptions and uncertainties.

Voting matters and shareholder proposals

• Shareholders will vote on EGM Proposals related to the XOMA transaction at an extraordinary general meeting.

• Proxy materials and a proxy card will be mailed to eligible shareholders for voting.

Board of directors and corporate governance

• Directors and executive officers of both companies may participate in the solicitation of proxies for the EGM Proposals.

• Information on directors, executive officers, and their share ownership is available in prior proxy statements.